ARTICLE SUMMARY:
SetPoint Medical recently reported positive clinical study results on a bioelectronic device therapy for rheumatoid arthritis, a disease that’s responsible for creating a $50 billion pharmaceutical market. The company is set to move on to its large pivotal study, advancing a device with substantial economic and potential safety advantages compared to RA drugs.
The developer of a new neuromodulation device therapy, SetPoint Medical Inc. has set its sights on one of the largest pharmaceutical markets, the treatment of rheumatoid arthritis (RA), which is a global market worth about $50 billion today. Despite this astronomical level of spending on drugs, RA is not effectively treated in many patients.
